Annual Drug Patent Expirations for ORACEA Oracea is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers. There are six…
Source
New patent expiration for Galderma Labs drug ORACEA Read Post »
This chart shows the drugs with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…
Source
Which pharmaceutical drugs have the most drug patents in Russian Federation? Read Post »
Annual Drug Patent Expirations for HETLIOZ+LQ Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in one NDA. It is available from one supplier. There are…
Source
Annual Drug Patent Expirations for TALICIA Talicia is a drug marketed by Redhill and is included in one NDA. It is available from one supplier. There are five patents protecting…
Source
Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are seven patents protecting…
Source
Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are twenty-seven…
Source
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Netherlands. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…
Source
Which pharmaceutical companies have the most SPCs in Netherlands? Read Post »
Annual Drug Patent Expirations for SKYCLARYS Skyclarys is a drug marketed by Reata Pharms and is included in one NDA. It is available from one supplier. There are six patents…
Source
Annual Drug Patent Expirations for LODOCO Lodoco is a drug marketed by Agepha Pharma Fz and is included in one NDA. It is available from one supplier. There are eight…
Source
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugPatentWatch.com
Source
New tentative approval for MYLAN drug efavirenz, emtricitabine and tenofovir alafenamide Read Post »
Get new actionable insights and updates from BiotechBlog
